GANX GAIN THERAPEUTICS INC Capital Structure Changes 8-K Filing 2023 - Termination of Agreement Gain Therapeutics terminated its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald, through which it sold 865,535 shares of Common Stock for $3.5 million.Get access to all SEC 8-K filings of the GAIN THERAPEUTICS INC